We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana Bets on Pharmacists to Lift Chronic Care Outcomes
Read MoreHide Full Article
Key Takeaways
Humana launches Pharmacist Quality Rewards program in Ohio to improve hypertension and diabetes outcomes.
HUM uses a pay-for-performance model with metrics like blood pressure and glycemic control tracking.
Community pharmacists provide testing, counseling and coordination to drive earlier interventions.
Humana Inc. (HUM - Free Report) , through its Medicaid arm Humana Healthy Horizons in Ohio, has partnered with CPESN USA to launch a Pharmacist Quality Rewards program, a value-based care initiative aimed at improving outcomes for members with hypertension and diabetes. The initiative emphasizes community-based care delivery by leveraging local pharmacy networks to close critical care gaps and expand access across Ohio.
At the core of the program is a pay-for-performance model aligned with key quality metrics such as blood pressure control and glycemic management. Pharmacists receive actionable patient-level insights, enabling them to flag missed screenings or out-of-range results. With patients visiting pharmacies more frequently than primary care providers, HUM is leveraging this touchpoint to drive earlier interventions and better adherence.
Execution is rooted in community-based settings, where pharmacists engage patients during routine prescription visits. They can conduct point-of-care testing, provide counseling and coordinate with prescribers when results signal the need for follow-up. This frequent interaction model strengthens monitoring and supports more timely interventions in chronic disease management.
The move reinforces Humana’s focus on embedding community-based providers into its broader care framework. By integrating pharmacists more deeply into day-to-day care delivery, Humana Healthy Horizons in Ohio is improving access to essential services and making care more convenient and consistent for members.
Better management of chronic conditions like hypertension and diabetes can help reduce hospital admissions and emergency care utilization, lowering overall medical costs for HUM. This, combined with potential improvements in quality ratings and reimbursement levels, can support steady revenue growth and margin stability, reinforcing the company’s long-term earnings outlook. Its total revenues of $129.7 billion rose 10.1% year over year in 2025. It expects total revenues to be at least $160 billion in 2026.
HUM’s Price Performance
Over the past year, HUM shares have fallen 32.3% compared with the industry’s decline of 43.1%.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.46 per share has witnessed one upward revision in the past 30 days, against no movement in the opposite direction. Globus Medical beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 18.8%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.7% year-over-year growth.
The Zacks Consensus Estimate for InnovAge Holding’s current-year earnings of 25 cents per share has witnessed one upward revision in the past 60 days, against no movement in the opposite direction. InnovAge Holding beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 87.5%. The consensus estimate for current-year revenues is pegged at $944.5 million, suggesting 10.6% year-over-year growth.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.61 per share has witnessed six upward revisions in the past 60 days, against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 40.4%. The consensus estimate for current-year revenues is pegged at $14.8 billion, suggesting 14.8% year-over-year growth.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Humana Bets on Pharmacists to Lift Chronic Care Outcomes
Key Takeaways
Humana Inc. (HUM - Free Report) , through its Medicaid arm Humana Healthy Horizons in Ohio, has partnered with CPESN USA to launch a Pharmacist Quality Rewards program, a value-based care initiative aimed at improving outcomes for members with hypertension and diabetes. The initiative emphasizes community-based care delivery by leveraging local pharmacy networks to close critical care gaps and expand access across Ohio.
At the core of the program is a pay-for-performance model aligned with key quality metrics such as blood pressure control and glycemic management. Pharmacists receive actionable patient-level insights, enabling them to flag missed screenings or out-of-range results. With patients visiting pharmacies more frequently than primary care providers, HUM is leveraging this touchpoint to drive earlier interventions and better adherence.
Execution is rooted in community-based settings, where pharmacists engage patients during routine prescription visits. They can conduct point-of-care testing, provide counseling and coordinate with prescribers when results signal the need for follow-up. This frequent interaction model strengthens monitoring and supports more timely interventions in chronic disease management.
The move reinforces Humana’s focus on embedding community-based providers into its broader care framework. By integrating pharmacists more deeply into day-to-day care delivery, Humana Healthy Horizons in Ohio is improving access to essential services and making care more convenient and consistent for members.
Better management of chronic conditions like hypertension and diabetes can help reduce hospital admissions and emergency care utilization, lowering overall medical costs for HUM. This, combined with potential improvements in quality ratings and reimbursement levels, can support steady revenue growth and margin stability, reinforcing the company’s long-term earnings outlook. Its total revenues of $129.7 billion rose 10.1% year over year in 2025. It expects total revenues to be at least $160 billion in 2026.
HUM’s Price Performance
Over the past year, HUM shares have fallen 32.3% compared with the industry’s decline of 43.1%.
Image Source: Zacks Investment Research
HUM’s Zacks Rank & Key Picks
HUM currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the Medical space are Globus Medical, Inc. (GMED - Free Report) , InnovAge Holding Corp. (INNV - Free Report) and BrightSpring Health Services, Inc. (BTSG - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.46 per share has witnessed one upward revision in the past 30 days, against no movement in the opposite direction. Globus Medical beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 18.8%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.7% year-over-year growth.
The Zacks Consensus Estimate for InnovAge Holding’s current-year earnings of 25 cents per share has witnessed one upward revision in the past 60 days, against no movement in the opposite direction. InnovAge Holding beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 87.5%. The consensus estimate for current-year revenues is pegged at $944.5 million, suggesting 10.6% year-over-year growth.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.61 per share has witnessed six upward revisions in the past 60 days, against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 40.4%. The consensus estimate for current-year revenues is pegged at $14.8 billion, suggesting 14.8% year-over-year growth.